Clovis Oncology managed to capture the spotlight at ASCO this morning with the news that the majority of advanced ovarian cancer patients in an early-stage trial benefited from their PARP inhibitor rucaparib. And in a clinical update Clovis also touted evidence of activity for its early-stage lung cancer drug targeted at EGFR-mutant patients. Its shares ($CLVS) skyrocketed 80% on the news.
There is bad news out of ASCO for Eli Lilly's Alimta, its blockbuster lung cancer drug that is already under a patent assault by Teva Pharmaceutical Industries: The drug did not hit its primary endpoints of showing improved progression-free survival without grade four adverse events in a comparison study.
Here's a roundup of news on approved drugs from this year's American Society of Clinical Oncology conference, comprising highlights from FierceBiotech 's weekend coverage as well as recent releases.
As the top cancer researchers gather in Chicago, the world's largest CRO is weighing in on how best to steer the future of oncology drug development, arguing that picking the right patients and biomarkers in early stages can mean the difference between a blockbuster and a late-phase failure.
CHICAGO--The showdown between Bristol-Myers Squibb ($BMY) and Merck ($MRK) over a new PD-1 approach to spurring an immune response to cancer didn't disappoint.
A technique known as metabolomics may enable an Alzheimer's disease blood test diagnosis before patients start displaying symptoms, Mayo Clinic scientists have concluded.
QPS is reaching out to Hepregen to boost its early stage development offerings, licensing the company's "liver-in-a-dish" technology for drug metabolism and pharmacokinetic testing.
Roche took two steps forward and one step back on the Avastin front today, as investigators laid out a clear advantage in adding the therapy to chemo for cervical cancer while finding no survival advantage when adding it to first-line treatment of an aggressive form of brain cancer.
Merck's team arrived at ASCO with some solid positive data backing their melanoma program for lambrolizumab (MK-3475). The pharma giant is readying a pair of late-stage clinical trials for melanoma and non-small cell lung cancer as they set their sights on completing a speedy set of applications for regulators.
Bayer and Onyx appear poised to expand sales of Nexavar (sorafenib). Investigators told the crowd at ASCO Sunday morning that their therapy almost doubled progression-free survival of treatment-resistant thyroid cancer patients, from a median 5.8 months in the control arm to 10.8 months in the treatment group.